UK markets closed

Gyre Therapeutics, Inc. (GYRE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
11.99-0.62 (-4.92%)
At close: 04:00PM EDT
11.99 0.00 (0.00%)
After hours: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.03B
Enterprise value 988.19M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)8.85
Price/book (mrq)18.10
Enterprise value/revenue 8.54
Enterprise value/EBITDA 45.18

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3247.54%
S&P500 52-week change 326.14%
52-week high 330.40
52-week low 33.15
50-day moving average 315.86
200-day moving average 314.42

Share statistics

Avg vol (3-month) 362.42k
Avg vol (10-day) 353.76k
Shares outstanding 585.51M
Implied shares outstanding 685.51M
Float 815.72M
% held by insiders 181.73%
% held by institutions 10.96%
Shares short (30 Apr 2024) 476.07k
Short ratio (30 Apr 2024) 41.03
Short % of float (30 Apr 2024) 41.19%
Short % of shares outstanding (30 Apr 2024) 40.09%
Shares short (prior month 28 Mar 2024) 4121.19k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 312 Jan 2023
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 331 Oct 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -75.76%
Operating margin (ttm)29.70%

Management effectiveness

Return on assets (ttm)11.03%
Return on equity (ttm)-99.09%

Income statement

Revenue (ttm)115.69M
Revenue per share (ttm)1.63
Quarterly revenue growth (yoy)9.00%
Gross profit (ttm)N/A
EBITDA 21.87M
Net income avi to common (ttm)-87.64M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)235.70%

Balance sheet

Total cash (mrq)37.35M
Total cash per share (mrq)0.44
Total debt (mrq)275k
Total debt/equity (mrq)0.31%
Current ratio (mrq)3.22
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)18.36M
Levered free cash flow (ttm)N/A